Ischemic Heart Disease Therapeutics
1. Ranexa patent expiration
Treatment: Treating chronic angina by administering an extended release form of ranolazine
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US6369062 | MENARINI INTL | Sustained release ranolazine formulations |
May, 2019
(6 years ago) | |
| US6503911 | MENARINI INTL | Sustained release ranolazine formulations |
May, 2019
(6 years ago) | |
| US6617328 | MENARINI INTL | Sustained release ranolazine formulations |
May, 2019
(6 years ago) | |
| US6525057 | MENARINI INTL | Sustained release ranolazine formulations |
May, 2019
(6 years ago) | |
| US6479496 | MENARINI INTL | Methods for treating angina with ranolazine |
May, 2019
(6 years ago) | |
| US6620814 | MENARINI INTL | Sustained release ranolazine formulations |
May, 2019
(6 years ago) | |
| US6864258 | MENARINI INTL | Sustained release ranolazine formulations |
May, 2019
(6 years ago) | |
| US6562826 | MENARINI INTL | Sustained release ranolazine formulations |
May, 2019
(6 years ago) | |
| US6852724 | MENARINI INTL | Sustained release ranolazine formulations |
May, 2019
(6 years ago) | |
| US6303607 | MENARINI INTL | Method for administering a sustained release ranolanolazine formulation |
May, 2019
(6 years ago) | |
Drugs and Companies using RANOLAZINE ingredient
Market Authorisation Date: 12 February, 2007
Dosage: TABLET, EXTENDED RELEASE
How can I launch a generic of RANEXA before it's drug patent expiration?
More Information on Dosage
RANEXA family patents
